Clinical Trials | December 11, 2025
Lilly drug cuts risk of disease progression or death by 80% in trial
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Subscribe To Our Newsletter & Stay Updated
